pSivida Announces Positive Phase IIa Trial Results in Liver Cancer

17-Feb-2005

Global nanotechnology company pSivida Limited announced that its trial in inoperable primary liver cancer patients continues to show excellent results. Data from the second patient cohort of the current Phase IIa trial has further demonstrated that BrachySil(TM) (32-P BioSilicon(TM)) is safe and effective in tumor regression with increased efficacy.

Results of the second group of 4 patients, 12 weeks after their BrachySil(TM) treatment, revealed an average tumor regression by volume of 80% as determined by CT scanning. In some smaller tumors 100% regression was observed, a level of performance not seen with other intratumoral approaches. The study also demonstrated that there were no product-related adverse effects. Patients will continue to be monitored for 6 months post treatment.

BrachySil(TM) is a micron-sized particle in which the isotope 32-phosphorus is immobilized. pSivida believes that this product is unique in that it demonstrates a very high degree of isotope retention, thus reducing the risk of soluble radioactive material affecting healthy hepatic tissue or entering the circulation and causing systemic toxicity.

Other news from the department research and development

Most read news

More news from our other portals

Discover the latest developments in battery technology!